Hemophilia pediatric research registry database
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial is a research registry that enrolls children with hemophilia A or B to collect health information. It may help researchers better understand bleeding risk and treatment needs over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have hemophilia A or hemophilia B.
- Your blood clotting level (FVIII for A, FIX for B) is between 1% and 25%.
- You can provide informed consent for the study.
- The study enrollment depends on completing the consent process (no consent means you can’t join).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects information about people with bleeding disorders like hemophilia A or B and von Willebrand disease. The goal is to better understand these conditions and improve care across participating treatment centers.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
This study is a registry (a large database) that collects information from people who have or may have a blood disorder. It helps researchers learn more about these conditions and improve care.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.